PK-PD modeling of buprenorphine in cats: intravenous and oral transmucosal administration

被引:138
|
作者
Robertson, SA
Lascelles, BDX
Taylor, PM
Sear, JW
机构
[1] Univ Florida, Coll Vet Med, Dept Large Anim Clin Sci, Gainesville, FL 32610 USA
[2] Taylor Monroe, Little Downham, Ely, England
[3] Univ Oxford, Nuffield Dept Anaesthet, Oxford, England
关键词
D O I
10.1111/j.1365-2885.2005.00677.x
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The pharmacokinetics and thermal antinociceptive effects of buprenorphine after intravenous (i.v.) or oral transmucosal (OTM) administration were studied in six adult cats. Plasma buprenorphine concentrations were measured using radioimmunoassay. in a crossover study after a dose of 2 0 mu g/kg given by the i.v. or OTM route. Oral-pH was measured. Blood for drug analyses was collected before, and at 1, 2, 4, 6, 10, 15, 30, and 60 min and at 2, 4, 6, 8, 12, and 24 h after treatment. Thermal thresholds were measured before treatment, then following treatment every 30 min to 6 h, every 1 hour to 12 h and at 24 hours postadministration. Plasma buprenorphine concentration effect relationships were analyzed using a log-linear effect model. Oral pH was 9 in each cat. Peak plasma buprenorphine concentration was lower and occurred later in the OTM group but median bioavailability was 116.3%. Thermal thresholds increased significantly between 30 and 360 min in both groups. Peak effect was at 90 min and there Was no difference at any time between the two groups. There was distinct hysteresis between plasma drug concentration and effect in both groups. Overall, OTM administration of buprenorphine is as effective as i.v. treatment and offers a simple, noninvasive method of administration which produces thermal antinociception for up to 6 h in cats.
引用
收藏
页码:453 / 460
页数:8
相关论文
共 50 条
  • [31] Pharmacokinetics of detomidine following intravenous or oral-transmucosal administration and sedative effects of the oral-transmucosal treatment in dogs
    Messenger, Kristen M.
    Hopfensperger, Marie
    Knych, Heather K.
    Papich, Mark G.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2016, 77 (04) : 413 - 420
  • [32] Pharmacokinetics and pharmacodynamic effects of oral transmucosal and intravenous administration of dexmedetomidine in dogs
    Dent, Brian T.
    Aarnes, Turi K.
    Wavreille, Vincent A.
    Lakritz, Jeffrey
    Lerche, Phillip
    KuKanich, Butch
    Pereira, Carolina H. Ricco
    Bednarski, Richard M.
    AMERICAN JOURNAL OF VETERINARY RESEARCH, 2019, 80 (10) : 969 - 975
  • [33] Systemic uptake of buprenorphine by cats after oral mucosal administration
    Robertson, SA
    Taylor, PM
    Sear, JW
    VETERINARY RECORD, 2003, 152 (22) : 675 - 678
  • [34] Mechanism-based PK-PD modeling for prediction of efficacy-safety
    Danhof, M.
    JOURNAL OF PHARMACY AND PHARMACOLOGY, 2007, 59 : A66 - A66
  • [35] PK-PD modeling with the ACE-inhibitor imidapril in hypertensive patients.
    Harder, S
    Thurmann, PA
    Ungethum, W
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1997, 61 (02) : PII88 - PII88
  • [36] Machine Learning and Artificial Intelligence in PK-PD Modeling: Fad, Friend, or Foe?
    Huang, Zhonghui
    Denti, Paolo
    Mistry, Hitesh
    Kloprogge, Frank
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 115 (04) : 652 - 654
  • [37] Application of PK-PD Modeling in Understanding Bystander Effect for Antibody Drug Conjugates
    Singh, Aman P.
    Shah, Dhaval K.
    JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2017, 44 : S27 - S28
  • [38] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING OF MIDAZOLAM-FLUMAZENIL INTERACTIONS
    FISET, P
    EGAN, T
    LEMMENS, H
    SHAFER, S
    STANSKI, D
    ANESTHESIOLOGY, 1993, 79 (3A) : A362 - A362
  • [39] The Pharmacokinetics/Pharmacodynamics of Resveratrol and Mechanism-based PK-PD Modeling Research
    Chen, Hui
    Liu, Xinxia
    Wan, Heng
    Zeng, Can
    FASEB JOURNAL, 2014, 28 (01):
  • [40] PHARMACOKINETIC-PHARMACODYNAMIC (PK-PD) MODELING FOR METFORMIN IN HEALTHY VOLUNTEERS.
    Kim, Y.
    Cho, S.
    Lee, D.
    Son, H.
    Roh, H.
    Son, M.
    Heo, Y.
    Park, K.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 : S48 - S48